Korean Medication Algorithm for Bipolar Disorder 2018 : Rapid Cycling
- Author:
Jong Hyun JEONG
1
;
Won Myong BAHK
;
Bo Hyun YOON
;
Duk In JON
;
Jeong Seok SEO
;
Won KIM
;
Jung Goo LEE
;
Young Sup WOO
;
Moon Doo KIM
;
Inki SOHN
;
Se Hoon SHIM
;
Hoo Rim SONG
;
Kyung Joon MIN
Author Information
1. Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
Bipolar disorder;
Rapid cycling;
KMAP-BP 2018
- MeSH:
Advisory Committees;
Antidepressive Agents;
Antipsychotic Agents;
Aripiprazole;
Bipolar Disorder;
Lithium;
Psychiatry;
Quetiapine Fumarate;
Valproic Acid
- From:
Mood and Emotion
2018;16(2):77-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder 2014 for rapid cycling.METHODS: The questionnaires, which were intended to survey experts for their opinions of medication used for rapid cycling, were completed by the review committee, which consisted of 84 Korean expert psychiatrists. We classified the responses into three categories. based on the lowest category in which the confidence interval fall (6.5≤ for first-line and 3.5≤ for high second-line treatment).RESULTS: The first-line treatment was the combination of a mood stabilizer and an atypical antipsychotic. This combination strategy was the treatment of choice for manic episodes. Additionally, a mood stabilizer with lamotrigine therapy and an atypical antipsychotic with lamotrigine combinations were the first-line treatments for the depressive phase. Atypical antipsychotic monotherapy, mood stabilizer monotherapy, the combination of two mood stabilizers, and the triple combination of mood stabilizers, atypical antipsychotics, and antidepressants were preferred as the next strategies. The first-line medications in all cases were valproate, quetiapine, olanzapine and aripiprazole. Lithium was the first-line medication in depressive and hypomanic episodes, and lamotrigine was the first-line medication for the treatment of the depressive phase.CONCLUSION: Compared to the surveys in 2014, the preference for atypical antipsychotics and lamotrigine have increased, and modalities used as a second-line treatment were more diverse.
